· Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio’s leadership team as it prepares to advance RBP-01 into the clinic · RBP-01 targets primary uveal melanoma, the most common primary eye cancer in adults and an indication with no approved therapies Turku, Finland and Geneva, Switzerland, 22 July2026 – ReBioPharma (“ReBio” […]
Lund, Sweden, 15 June 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) announced today the appointment of Adam Cutler as Chief Financial Officer (CFO) and a member of the Executive Committee, effective June 22, 2026. Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June 22 […]
The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late‑stage development, global regulatory and operational expertise as MinervaX enters its next phase of growth Builds on robust Phase II results, paving the way for a registrational trial and advancing efforts to meet the urgent global need for a GBS […]
12 March 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board. Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology […]
Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical development candidates later in 2026 COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed […]
